



IHH Healthcare Berhad

IHH HEALTHCARE BERHAD
(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT
31 MARCH 2024

**UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME
FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024**

	Note	1st quarter ended		Variance %
		31 Mar 2024 RM'000	31 Mar 2023 RM'000	
Revenue	1	5,955,460	5,142,406	16%
Other operating income	2	102,853	1,104,441	-91%
Inventories and consumables		(1,192,624)	(1,043,322)	-14%
Purchased and contracted services		(471,078)	(464,166)	-1%
Staff costs	3	(2,272,778)	(1,905,809)	-19%
Depreciation and impairment of property, plant and equipment	4	(294,146)	(266,021)	-11%
Depreciation of right-of-use ("ROU") assets	4	(106,614)	(92,253)	-16%
Amortisation of intangible assets	4	(13,206)	(11,141)	-19%
Operating lease expenses		(30,885)	(27,507)	-12%
Other operating expenses		(721,204)	(669,860)	-8%
Finance income	5	78,731	39,588	99%
Finance costs	5	(257,438)	(185,221)	-39%
Net monetary gain arising from hyperinflationary economy		146,096	164,758	-11%
Share of profits of associates (net of tax)		6,753	6,113	10%
Share of profits of joint ventures (net of tax)		692	502	38%
Profit before tax		930,612	1,792,508	-48%
Income tax expense	6	(5,211)	(240,544)	98%
Profit for the period		925,401	1,551,964	-40%
Other comprehensive income, net of tax				
<i>Items that are or may be reclassified subsequently to profit or loss</i>				
Foreign currency translation differences from foreign operations	7	173,930	50,059	NM
Realisation of FCTR ¹ upon disposal of subsidiaries		-	10,726	-100%
Hyperinflationary adjustments		426,116	538,135	-21%
Hedge of net investments in foreign operations	7	8,273	322,076	-97%
Cash flow hedge		(15,925)	(9,774)	-63%
Costs of hedging		(936)	(430)	-118%
		591,458	910,792	-35%
<i>Items that will not be reclassified subsequently to profit or loss</i>				
Remeasurement of defined benefit liabilities		(11,408)	(1,073)	NM
Total other comprehensive income for the period, net of tax		580,050	909,719	-36%
Total comprehensive income for the period		1,505,451	2,461,683	-39%
Profit attributable to:				
Owners of the Company		767,972	1,390,519	-45%
Non-controlling interests		157,429	161,445	-2%
Profit for the period		925,401	1,551,964	-40%
Total comprehensive income attributable to:				
Owners of the Company		1,312,272	2,239,610	-41%
Non-controlling interests		193,179	222,073	-13%
Total comprehensive income for the period		1,505,451	2,461,683	-39%
Earnings per share (sen)				
Basic		8.72	15.79	-45%
Diluted		8.72	15.79	-45%

NM: Not meaningful

Note:

¹: Foreign currency translation reserve

UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024

SUPPLEMENTARY INFORMATION

	Note	1st quarter ended		Variance %
		31 Mar 2024 RM'000	31 Mar 2023 RM'000	
Profit attributable to owners of the Company, excluding EI^{vi}		402,846	329,866	22%
Add/(Less): Exceptional items ("EI")				
Gain on disposal of subsidiaries ⁱ	2	-	981,417	
Gain on disposal of asset ⁱⁱ		2,614	-	
Exchange difference on net borrowings, net of changes in fair value of financial derivatives ⁱⁱⁱ	5	(46,217)	7,148	
Deferred tax credits ^{iv}	6	293,359	-	
Net monetary gain arising from hyperinflationary economy ^v		146,096	164,758	
		<u>395,852</u>	<u>1,153,323</u>	
Less: Tax effects on EI		11,554	(1,644)	
Less: Non-controlling interests' share of EI		<u>(42,280)</u>	<u>(91,026)</u>	
		<u>365,126</u>	<u>1,060,653</u>	
Profit attributable to owners of the Company		<u>767,972</u>	<u>1,390,519</u>	-45%
Earnings per share, excluding EI^{vi} (sen)				
Basic		4.57	3.75	22%
Diluted		4.57	3.75	22%

Note:

"Acibadem Holdings" as referred to throughout this financial report includes the wholly-owned Integrated Healthcare Turkey Yatirimlari Limited Group, which owns approximately 90% interest in Acibadem Sağlık Yatirimlari Holding A.Ş. Group.

- i. Gain on disposal of IMU Health Sdn Bhd and its subsidiaries (collectively, "IMU Health") of RM862.0 million and Gleneagles Chengdu Hospital Company Limited ("Gleneagles Chengdu Hospital") of RM116.5 million.
- ii. Gain on disposal of Fortis Malar Hospital.
- iii. Exchange differences arising from foreign currency denominated borrowings, lease liabilities, payables, cash and receivables, recognised by Acibadem Holdings.
It is netted off with the fair value changes of the financial derivatives which was entered to hedge a portion of Acibadem Holdings' foreign currency denominated borrowings.
- iv. Deferred tax credits arising from the revaluation of certain assets in the tax financials of the Group's entities in Turkiye, as allowed by the Turkiye government.
- v. Net increase in purchasing power from the net monetary position of the Group's operations in Turkiye, upon the application of MFRS 129, *Financial Reporting in Hyperinflationary Economies*.
- vi. Net of tax and minority interests.

The unaudited Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the 2023 Audited Financial Statements and the accompanying explanatory notes attached to this financial report.

EXPLANATORY NOTES TO THE STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

The Group's reported results, across the periods, was impacted by the relative movements of Ringgit Malaysia ("RM") against the exchange rates of the countries that the Group operates in. The RM weakened against Singapore Dollars ("SGD") and strengthened against Turkish Lira ("TL") in the current period as compared to the corresponding period last year.

The Group's reported results, across the periods, was also impacted by the relative movements of inflation rates in Turkiye, upon the application of MFRS 129, *Financial Reporting in Hyperinflationary Economies* ("MFRS 129") to the Group's entities in Turkiye. Refer to Section A4 for details.

In addition to variances arising from the above-mentioned effects of the relative movement in exchange rates and inflation rates in Turkiye, the following notes explain the major fluctuations in the statement of profit or loss and other comprehensive income for the quarter ended 31 March 2024.

Refer to Section B1 for performance review of the Group's major operating segments.

1. Q1 2024 revenues were higher as compared to Q1 2023 driven by a sustained demand for quality healthcare services, a case-mix of more acute patients and price adjustments to counter inflation. Ozel Kent Saglik Hizmetleri ve Malzemeleri Sanayi Ticaret A.S. ("Kent"), which was acquired on 14 February 2023, and Bedrock Healthcare Sdn. Bhd. ("Bedrock"), which was acquired on 29 February 2024, also contributed to the increase.
2. Q1 2024 other operating income decreased from a high base in Q1 2023 whereby gains on disposal of IMU Health and Gleneagles Chengdu Hospital of RM862.0 million and RM116.5 million was recognised respectively.
3. Q1 2024 staff costs increased as the Group expands its capacity to cater for higher demand for its services and annual increments.
4. Q1 2024 depreciation, amortisation and impairment expense increased when the property, plant and equipment, right-of-use assets and intangible assets of the Group's subsidiaries in Turkiye increased with higher inflation rates in Turkiye during the period.
5. Acibadem Holdings recognised exchange differences arising from the translation of its unhedged foreign currency denominated borrowings, lease liabilities, payables, cash and receivables as finance income or finance cost. Acibadem Holdings manages its foreign exchange exposures by entering into cross currency swaps ("CCS") and foreign exchange forward contracts. The Group recognised a net loss of RM46.2 million in Q1 2024 as compared to a net gain of RM7.1 million in Q1 2023.

Excluding the above, Q1 2024 net finance costs increased mainly due to higher prevailing interest rates in 2024 and decrease in capitalisation of borrowing cost for Parkway Shanghai Hospital upon completion of construction in February 2023.

6. Refer to Section B5 for details on income tax expenses.
7. The Group's foreign currency translation differences from foreign operations arise mainly from the translation of the net assets of its Singapore, India and Europe operations.

Parkway Life Real Estate Investment Trust ("PLife REIT") hedges its interest in the net assets of its Japanese operations. The effective portion of the hedge was recognised as a hedge of net investments in the statement of other comprehensive income, which offsets the foreign currency translation differences from the translation of the net assets of its Japanese operations.

Note:

Key exchange rates used to translate the YTD results of overseas subsidiaries into RM:

	31 Mar 2024	31 Mar 2023
1 SGD	3.5241	3.2906
1 TL	0.1471	0.2323

**UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2024**

		31 Mar 2024	31 Dec 2023
	Note	RM'000	RM'000
Assets			
Property, plant and equipment		13,966,997	13,413,941
Right-of-use assets		7,239,761	7,119,066
Investment properties		4,022,870	4,105,768
Goodwill on consolidation	1	14,624,010	14,295,951
Other intangible assets		3,057,667	2,963,011
Interests in associates		147,507	139,761
Interests in joint ventures		18,485	6,813
Other financial assets		233,741	233,393
Trade and other receivables	2	269,703	128,840
Tax recoverables		459,473	422,193
Derivative assets		156,745	138,018
Deferred tax assets		565,268	512,495
Total non-current assets		44,762,227	43,479,250
Development properties		79,635	79,579
Inventories		666,156	639,837
Trade and other receivables	2	3,300,730	3,084,027
Tax recoverables		24,538	31,244
Other financial assets		257,140	286,008
Derivative assets		134,808	212,898
Cash and cash equivalents		2,212,821	2,379,123
		6,675,828	6,712,716
Assets classified as held for sale		196	194
Total current assets		6,676,024	6,712,910
Total assets		51,438,251	50,192,160

**UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2024**

	31 Mar 2024	31 Dec 2023
Note	RM'000	RM'000
Equity		
Share capital	19,691,636	19,691,630
Other reserves	1,915,363	1,573,882
Retained earnings	8,181,466	7,840,027
Total equity attributable to owners of the Company	29,788,465	29,105,539
Non-controlling interests	3,234,609	3,253,111
Total equity	33,023,074	32,358,650
Liabilities		
Loans and borrowings	6,749,150	6,650,567
Lease liabilities	1,399,247	1,412,669
Employee benefits	190,728	182,950
Trade and other payables	506,514	454,222
Derivative liabilities	6,488	12,936
Deferred tax liabilities	1,607,773	1,663,349
Total non-current liabilities	10,459,900	10,376,693
Bank overdrafts	37,171	77,885
Loans and borrowings	1,631,537	1,660,820
Lease liabilities	260,599	247,822
Employee benefits	156,486	158,354
Trade and other payables	5,459,353	4,951,735
Derivative liabilities	2,623	7,159
Tax payable	407,508	353,042
Total current liabilities	7,955,277	7,456,817
Total liabilities	18,415,177	17,833,510
Total equity and liabilities	51,438,251	50,192,160
Net assets per share attributable to owners of the Company ¹ (RM)	3.38	3.30

¹: Based on 8,807.0 million and 8,807.0 million shares issued as at 31 March 2024 and 31 December 2023 respectively.

The unaudited Consolidated Statement of Financial Position should be read in conjunction with the 2024 Audited Financial Statements and the accompanying explanatory notes attached to this financial report.

EXPLANATORY NOTES TO THE STATEMENT OF FINANCIAL POSITION

The Group's reported financial position as at 31 March 2024 was impacted by the movements in RM against the exchange rates of the countries that the Group operates in. The RM weakened against SGD and strengthened against TL for the period ended 31 March 2024.

The Group's reported financial position as at 31 March 2024 was also impacted by the movements of the price index in Turkiye, upon the application of MFRS 129 to the Group's entities in Turkiye. Inflation rates in Turkiye increased for the period ended 31 March 2024. Refer to Section A4 for details.

In addition to variances arising from the above-mentioned effects of the movement in exchange rates and inflation rates in Turkiye, the following notes explain the major fluctuations in the statement of financial position as at 31 March 2024.

1. Goodwill increased mainly due to acquisition of Bedrock on 29 February 2024 which resulted in goodwill on acquisition of RM142.0 million, translational effects from a strengthened SGD against RM during the period and from MFRS 129 effects.
2. Trade and other receivables increased mainly due to higher revenue and advance given in relation to hospital renovations.
3. Current trade and other payables increased mainly due to dividends declared by the Company and not paid out as at 31 March 2024. The dividends was paid on 26 April 2024.

Note:

Key closing exchange rates used to translate the financial position of overseas subsidiaries into RM:

	31 Mar 2024	31 Dec 2023
1 SGD	3.5112	3.4990
1 TL	0.1471	0.1568

UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2024

	Attributable to owners of the Company											Total equity RM'000	
	Non-distributable							Distributable					
	Share capital RM'000	Share option reserve RM'000	Revaluation reserve RM'000	Fair value reserve RM'000	Hedge reserve RM'000	Cost of hedging reserve RM'000	Capital reserve RM'000	Legal reserve RM'000	Foreign currency translation reserve RM'000	Retained earnings RM'000	Total RM'000	Non-controlling interests RM'000	
At 1 January 2024	19,691,630	25,065	83,434	47,395	(54,974)	51	(4,040,148)	46,926	5,466,133	7,840,027	29,105,539	3,253,111	32,358,650
Foreign currency translation differences from foreign operations	-	-	-	-	-	-	-	-	172,313	-	172,313	1,617	173,930
Hyperinflationary adjustments	-	-	-	-	(5,271)	-	(10,479)	2,059	341,850	67,751	395,910	30,206	426,116
Hedge of net investments in foreign operations	-	-	-	-	-	-	-	-	2,939	-	2,939	5,334	8,273
Cash flow hedge	-	-	-	-	(16,352)	-	-	-	-	-	(16,352)	427	(15,925)
Costs of hedging	-	-	-	-	-	(333)	-	-	-	-	(333)	(603)	(936)
Remeasurement of defined benefit liabilities	-	-	-	-	-	-	-	-	-	(10,177)	(10,177)	(1,231)	(11,408)
Total other comprehensive income for the period	-	-	-	-	(21,623)	(333)	(10,479)	2,059	517,102	57,574	544,300	35,750	580,050
Profit for the period	-	-	-	-	-	-	-	-	-	767,972	767,972	157,429	925,401
Total comprehensive income for the period	-	-	-	-	(21,623)	(333)	(10,479)	2,059	517,102	825,546	1,312,272	193,179	1,505,451
<i>Contributions by and distributions to owners</i>													
Share-based payment transactions	-	1,422	-	-	-	-	-	-	-	-	1,422	-	1,422
Transfer to share capital for share options exercised	6	-	-	-	-	-	-	-	-	-	6	-	6
Cancellation of vested share options	-	(332)	-	-	-	-	-	-	-	332	-	-	-
Dividends to owners of the Company	-	-	-	-	-	-	-	-	-	(484,385)	(484,385)	-	(484,385)
Dividends to non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	(108,716)	(108,716)
Remeasurement of liabilities on put options granted to non-controlling interests	-	-	-	-	-	(117,285)	-	-	(13,696)	-	(130,981)	(103,103)	(234,084)
Transfer per statutory requirements	-	-	-	-	-	-	-	54	-	(54)	-	-	-
	6	1,090	-	-	-	(117,285)	-	54	(13,696)	(484,107)	(613,938)	(211,819)	(825,757)
Changes in ownership interests in subsidiaries	-	-	-	-	-	(15,408)	-	-	-	-	(15,408)	138	(15,270)
Total transactions with owners	6	1,090	-	-	-	(132,693)	-	54	(13,696)	(484,107)	(629,346)	(211,681)	(841,027)
At 31 March 2024	19,691,636	26,155	83,434	47,395	(76,597)	(282)	(4,183,320)	49,039	5,969,539	8,181,466	29,788,465	3,234,609	33,023,074

UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2024

	Attributable to owners of the Company								Distributable				
	Non-distributable												
	Share capital	Share option reserve	Revaluation reserve	Fair value reserve	Hedge reserve	Cost of hedging reserve	Capital reserve	Legal reserve	Foreign currency translation reserve	Retained earnings	Total	Non-controlling interests	Total equity
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
At 1 January 2023	19,684,881	22,783	83,434	-	8,274	791	(3,998,823)	36,380	3,689,021	6,665,236	26,191,977	2,967,080	29,159,057
Foreign currency translation differences from foreign operations	-	-	-	-	-	-	-	-	223,272	-	223,272	(173,213)	50,059
Realisation of FCTR upon disposal of subsidiaries	-	-	-	-	-	-	-	-	10,726	-	10,726	-	10,726
Hyperinflationary adjustments	-	-	-	-	-	-	(9,933)	1,902	508,847	3,716	504,532	33,603	538,135
Hedge of net investments in foreign operations	-	-	-	-	-	-	-	-	114,466	-	114,466	207,610	322,076
Cash flow hedge	-	-	-	-	(3,474)	-	-	-	-	-	(3,474)	(6,300)	(9,774)
Costs of hedging	-	-	-	-	-	(153)	-	-	-	-	(153)	(277)	(430)
Remeasurement of defined benefit liabilities	-	-	-	-	-	-	-	-	-	(278)	(278)	(795)	(1,073)
Total other comprehensive income for the period	-	-	-	-	(3,474)	(153)	(9,933)	1,902	857,311	3,438	849,091	60,628	909,719
Profit for the period	-	-	-	-	-	-	-	-	-	1,390,519	1,390,519	161,445	1,551,964
Total comprehensive income for the period	-	-	-	-	(3,474)	(153)	(9,933)	1,902	857,311	1,393,957	2,239,610	222,073	2,461,683
<i>Contributions by and distributions to owners</i>													
Share-based payment transactions	-	2,217	-	-	-	-	-	-	-	-	2,217	-	2,217
Transfer to share capital for share options exercised	6,749	(1,260)	-	-	-	-	-	-	-	-	5,489	-	5,489
Cancellation of vested share options	-	(1,389)	-	-	-	-	-	-	-	1,389	-	-	-
Dividends to owners of the Company	-	-	-	-	-	-	-	-	-	(616,489)	(616,489)	-	(616,489)
Dividends to non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	(101,396)	(101,396)
Remeasurement of liabilities on put options granted to non-controlling interests	-	-	-	-	-	-	(3,370)	-	-	-	(3,370)	(2,415)	(5,785)
Transfer per statutory requirements	-	-	-	-	-	-	-	28	-	(28)	-	-	-
	6,749	(432)	-	-	-	-	(3,370)	28	-	(615,128)	(612,153)	(103,811)	(715,964)
Changes in ownership interests in subsidiaries	-	-	-	-	(3)	-	1,506	-	1	-	1,504	275	1,779
Total transactions with owners	6,749	(432)	-	-	(3)	-	(1,864)	28	1	(615,128)	(610,649)	(103,536)	(714,185)
Disposal of subsidiaries	-	-	-	-	-	-	(21,574)	-	-	19,051	(2,523)	54,895	52,372
At 31 March 2023	19,691,630	22,351	83,434	-	4,797	638	(4,032,194)	38,310	4,546,333	7,463,116	27,818,415	3,140,512	30,958,927

The unaudited Consolidated Statement of Changes in Equity should be read in conjunction with the 2024 Audited Financial Statements and the accompanying explanatory notes attached to this financial report.

**UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2024**

	Financial period ended	
	31 Mar 2024 RM'000	31 Mar 2023 RM'000
Cash flows from operating activities		
Profit before tax	930,612	1,792,508
Adjustments for:		
Dividend income	(112)	-
Finance income	(78,731)	(39,588)
Finance costs	257,438	185,221
Depreciation and impairment of property, plant and equipment	294,146	266,021
Depreciation of ROU assets	106,614	92,253
Amortisation of intangible assets	13,206	11,141
Impairment loss made:		
- Trade and other receivables	15,249	34,070
Write-off:		
- Property, plant and equipment	230	95
- Trade and other receivables	10,922	1,125
- Inventories	846	1,459
Gain on disposal of property, plant and equipment	(968)	(3,486)
Gain on disposal of subsidiaries	-	(981,417)
Gain on disposal of asset	(2,614)	-
Change in fair value of investment properties	(144)	792
Share of profits of associates (net of tax)	(6,753)	(6,113)
Share of profits of joint ventures (net of tax)	(692)	(502)
Equity-settled share-based payment	1,422	2,217
Net monetary gain arising from hyperinflationary economy	(146,096)	(164,758)
Operating profit before changes in working capital	1,394,575	1,191,038
Changes in working capital:		
Development properties	(56)	286
Inventories	(59,652)	(81,895)
Trade and other receivables	(451,875)	(286,026)
Trade and other payables	68,419	(47,973)
Cash generated from operations	951,411	775,430
Tax paid	(120,075)	(114,445)
Net cash from operating activities	831,336	660,985
Cash flows from investing activities		
Interest received	38,785	25,948
Acquisition of a subsidiary/business, net of cash and cash equivalents acquired	(208,976)	(254,014)
Purchase of other financial assets	(13,642)	(34,536)
Net (placement)/withdrawal of fixed deposits with tenor of more than 3 months	(90,787)	117,469
Purchase of property, plant and equipment	(638,354)	(256,080)
Cost capitalised and purchase of investment properties	(5,080)	(16,680)
Development and purchase of intangible assets	(29,577)	(6,475)
Net cash inflow from disposal of subsidiaries	-	1,175,176
Proceeds from disposal of other financial assets	135,388	25,670
Proceeds from disposal of property, plant and equipment	23,193	25,693
Proceeds from disposal of asset	67,694	-
Dividends received from associates and joint ventures	329	13,580
Net cash (used in)/from investing activities	(721,027)	815,751

**UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2024**

	Financial period ended	
	31 Mar 2024 RM'000	31 Mar 2023 RM'000
Cash flows from financing activities		
Finance costs paid	(106,524)	(102,768)
Proceeds from loans and borrowings	1,288,382	1,122,473
Repayment of loans and borrowings	(1,109,147)	(1,007,971)
Payment of lease liabilities	(103,122)	(129,032)
Dividends paid to non-controlling interests	(108,716)	(101,396)
Proceeds from exercise of share options	6	5,489
Acquisition of non-controlling interests	(15,080)	-
Net cash used in financing activities	(154,201)	(213,205)
Net (decrease)/increase in cash and cash equivalents	(43,892)	1,263,531
Effect of exchange rate fluctuations on cash and cash equivalents held	(81,696)	(54,738)
Cash and cash equivalents at beginning of the period	2,301,238	3,662,352
Cash and cash equivalents at end of the period	2,175,650	4,871,145

Cash and cash equivalents

Cash and cash equivalents in the statement of cash flows comprises the following amounts from the statement of financial position:

	31 Mar 2024 RM'000	31 Mar 2023 RM'000
Cash and bank balances	892,227	2,534,498
Fixed deposits with tenor of 3 months or less	1,300,754	583,000
Deposits placed in escrow account	19,184	1,804,834
Restricted cash	656	647
Cash and cash equivalents in the statement of financial position	2,212,821	4,922,979
Less:		
- Bank overdrafts	(37,171)	(51,834)
Cash and cash equivalents in the statement of cash flows	2,175,650	4,871,145

Deposits placed in escrow account

These are the amounts deposited in accordance with the requirements of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers Regulations) (“SEBI (SAST) Regulations”) relating to the Group’s Mandatory Open Offer (“Offer”) to acquire up to an additional 197,025,660 and 4,894,308 equity shares of Fortis Healthcare Limited (“Fortis”) and Fortis Malar Hospitals Limited (“Malar”) respectively (see Section A14). These amounts can only be released in the manner prescribed in Clause 17(10) of the SEBI (SAST) Regulations. In December 2023, approximately RM1,815.2 million placed in the escrow account was replaced by a bankers’ guarantee.

The unaudited Consolidated Statement of Cash Flows should be read in conjunction with the 2023 Audited Financial Statements and the accompanying explanatory notes attached to this financial report.

**A NOTES TO THE INTERIM FINANCIAL REPORT
FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024**

A1 BASIS OF PREPARATION

a) Basis of accounting

These unaudited consolidated interim financial report are prepared in accordance with the applicable disclosure provisions of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, MFRS 134, *Interim Financial Reporting* in Malaysia and IAS 34, *Interim Financial Reporting*. They do not include all of the information required for full annual financial statements and should be read in conjunction with the audited consolidated financial statements of the Group for the financial year ended 31 December 2023 (“2023 Audited Financial Statements”).

The 2023 Audited Financial Statements were prepared under Malaysian Financial Reporting Standards (“MFRSs”).

b) Material accounting policies

The accounting policies and presentation adopted for this consolidated interim financial report are consistent with those adopted for the 2023 Audited Financial Statements.

A2 AUDIT REPORT IN THE ANNUAL FINANCIAL STATEMENTS

The 2023 Audited Financial Statements were not subjected to any qualification.

A3 SEASONALITY OF OPERATIONS

Inpatient and outpatient revenue and volume are generally lower during festive periods and summer months in each of the relevant countries in which the Group operates and other holiday periods. Conversely, patient volumes and thus inpatient and outpatient revenue are highest during the winter months in some markets. As the Group is continuously expanding, the effects of seasonality may not be obvious from the Group’s financial statements.

**A NOTES TO THE INTERIM FINANCIAL REPORT
FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024**

**A4 SIGNIFICANT UNUSUAL ITEMS AFFECTING ASSETS, LIABILITIES, EQUITY, NET
INCOME OR CASH FLOWS**

There were no unusual items affecting assets, liabilities, equity, net income or cash flows due to their nature, size or incidence for the financial period ended 31 March 2024, other than the effects of the application to the Group's entities in Turkiye of MFRS 129 below.

Effects of application of MFRS129

	Before hyperinflationary adjustments RM'000	Adjustments RM'000	After hyperinflationary adjustments RM'000
<u>Statement of profit or loss</u>			
Revenue	5,945,371	10,089	5,955,460
Other operating income	103,157	(304)	102,853
Inventories and consumables	(1,178,331)	(14,293)	(1,192,624)
Purchased and contracted services	(470,718)	(360)	(471,078)
Staff costs	(2,266,100)	(6,678)	(2,272,778)
Depreciation and impairment of property, plant and equipment	(241,936)	(52,210)	(294,146)
Depreciation of ROU assets	(85,614)	(21,000)	(106,614)
Amortisation of intangible assets	(10,951)	(2,255)	(13,206)
Operating lease expenses	(30,827)	(58)	(30,885)
Other operating expenses	(720,278)	(926)	(721,204)
Finance income	74,753	3,978	78,731
Finance costs	(248,378)	(9,060)	(257,438)
Net monetary gain from hyperinflationary economy	-	146,096	146,096
Share of profits of associates (net of tax)	6,753	-	6,753
Share of profits of joint ventures (net of tax)	692	-	692
Profit before tax	877,593	53,019	930,612
Income tax expense	(187,864)	182,653	(5,211)
Profit for the period	689,729	235,672	925,401
Profit attributable to:			
Owners of the Company	557,126	210,846	767,972
Non-controlling interests	132,603	24,826	157,429
Profit for the period	689,729	235,672	925,401

**A NOTES TO THE INTERIM FINANCIAL REPORT
FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024**

<u>Statement of financial position</u>	Before hyperinflationary adjustments RM'000	Adjustments RM'000	After hyperinflationary adjustments RM'000
Non-current assets			
Property, plant and equipment	11,978,559	1,988,438	13,966,997
Right-of-use assets	6,613,841	625,920	7,239,761
Goodwill on consolidation	13,134,848	1,489,162	14,624,010
Other intangible assets	2,083,960	973,707	3,057,667
Trade and other receivables	269,375	328	269,703
Deferred tax assets	504,633	60,635	565,268
Curent assets			
Inventories	631,884	34,272	666,156
Equity			
Other reserves	(1,907,026)	3,822,389	1,915,363
Retained earnings	7,927,446	254,020	8,181,466
Non-controlling interests	2,758,149	476,460	3,234,609
Non-current liabilities			
Deferred tax liabilities	988,180	619,593	1,607,773

A5 CHANGE IN ACCOUNTING ESTIMATES

There were no changes in the estimates of amounts reported in prior financial years that may have a material effect in the current quarter and financial period.

In preparing the unaudited consolidated interim financial report, the significant judgments made by the management in applying the Group's accounting policies and key sources of estimating uncertainty were consistent with those applied to the 2023 Audited Financial Statements.

A6 DEBT AND EQUITY SECURITIES

Between 1 January 2024 to 31 March 2024, the Company issued 1,000 new ordinary shares pursuant to the exercise of vested Enterprise Option Scheme ("EOS") units.

Except as disclosed above, there were no other issuance of shares, share buy-backs and repayments of debt and equity securities by the Company during the financial period from 1 January 2024 to 31 March 2024.

As at 31 March 2024, the issued share capital of the Company comprised of 8,806,992,463 ordinary shares.

**A NOTES TO THE INTERIM FINANCIAL REPORT
FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024**

A7 DIVIDENDS PAID

There were no dividends paid during the financial period ended 31 March 2024.

A8 SEGMENT REPORTING

There has been no significant changes in the basis of segmentation or in the basis of measurement of segment profit or loss from the 2023 Audited Financial Statements.

The Group's reportable segments comprise:

- Hospital and healthcare
 - Singapore
 - Malaysia
 - India
 - Greater China
 - Turkiye and Europe
 - Southeast Asia
- IMU Health
- Labs
- PLife REIT
- Others

Except for IMU Health, Labs and PLife REIT, the strategic business units offer hospital and healthcare services in different locations and are managed separately. IMU Health is an educational service provider, Labs is a diagnostic laboratory service provider, while PLife REIT is a real estate investment trust. Others comprises the Group's corporate office as well as other investment holding entities.

Management monitors the operating results of each business unit for the purpose of making decisions on resource allocation and performance assessment. Performance is measured based on segment earnings before interest, tax, depreciation, amortisation, exchange differences and other non-operational items ("EBITDA").

**A NOTES TO THE INTERIM FINANCIAL REPORT
FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024**

A8 SEGMENT REPORTING

Financial period ended 31 March 2024

	Hospital and Healthcare										
	Singapore RM'000	Malaysia RM'000	India RM'000	Greater China RM'000	Turkiye and Europe RM'000	Southeast Asia RM'000	Labs RM'000	PLife REIT RM'000	Others RM'000	Eliminations RM'000	Total RM'000
<i>Revenue and expenses</i>											
Revenue from external customers	1,550,991	954,569	981,452	368,889	1,802,768	-	257,050	38,247	1,494	-	5,955,460
Inter-segment revenue	3,466	1,993	505	-	2,756	-	190,608	68,311	81,318	(348,957)	-
Total segment revenue	1,554,457	956,562	981,957	368,889	1,805,524	-	447,658	106,558	82,812	(348,957)	5,955,460
EBITDA	468,616	239,312	185,510	24,555	364,619	(8)	95,853	83,401	16,248	(112,518)	1,365,588
Depreciation and impairment of property, plant and equipment	(50,758)	(57,514)	(36,211)	(30,000)	(100,371)	-	(9,219)	(7,104)	(2,969)	-	(294,146)
Depreciation of ROU assets	(84,808)	(6,660)	(6,208)	(18,036)	(38,442)	-	(10,733)	(3,385)	(1,794)	63,452	(106,614)
Amortisation of intangible assets	-	(194)	(3,080)	(503)	(3,432)	-	(5,998)	-	(2,558)	2,559	(13,206)
Foreign exchange differences	(188)	(186)	(8,722)	(61)	4,171	-	(255)	9,437	(2,654)	-	1,542
Finance income	9,344	2,183	16,049	74	42,199	2	5,588	15,772	25,918	(38,398)	78,731
Finance costs	(45,667)	(1,041)	(28,146)	(60,754)	(162,054)	-	(4,740)	(9,218)	(29,292)	83,474	(257,438)
Net monetary gain arising from hyperinflationary economy	-	-	-	-	142,921	-	3,175	-	-	-	146,096
Share of profits of associates (net of tax)	-	-	2,394	-	-	4,359	-	-	-	-	6,753
Share of profits of joint ventures (net of tax)	328	93	187	-	-	-	84	-	-	-	692
Others	-	-	2,614	-	-	-	-	-	-	-	2,614
Profit/(Loss) before tax	296,867	175,993	124,387	(84,725)	249,611	4,353	73,755	88,903	2,899	(1,431)	930,612
Income tax expense/(credit)	(55,820)	(48,106)	(30,192)	(4,038)	163,277	-	(15,652)	(5,569)	(9,111)	-	(5,211)
Profit/(Loss) for the period	241,047	127,887	94,195	(88,763)	412,888	4,353	58,103	83,334	(6,212)	(1,431)	925,401
<i>Assets and liabilities</i>											
Cash and cash equivalents	19,983	295,875	115,142	95,851	387,996	7,592	52,895	125,220	1,112,267	-	2,212,821
Other assets	26,053,001	6,826,956	8,585,686	3,080,704	10,544,387	59,552	2,433,847	5,505,185	5,355,396	(19,219,284)	49,225,430
Segment assets as at 31 March 2024	26,072,984	7,122,831	8,700,828	3,176,555	10,932,383	67,144	2,486,742	5,630,405	6,467,663	(19,219,284)	51,438,251
Loans and borrowings	-	144,864	625,195	3,732,526	779,335	-	7,088	2,950,638	141,041	-	8,380,687
Other liabilities	15,505,724	1,048,147	2,910,207	804,825	3,689,581	2,266	496,030	426,521	4,553,537	(19,402,348)	10,034,490
Segment liabilities as at 31 March 2024	15,505,724	1,193,011	3,535,402	4,537,351	4,468,916	2,266	503,118	3,377,159	4,694,578	(19,402,348)	18,415,177

**A NOTES TO THE INTERIM FINANCIAL REPORT
FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024**

Financial period ended 31 March 2023*

	Hospital and Healthcare						IMU Health RM'000	Labs RM'000	PLife REIT RM'000	Others RM'000	Eliminations RM'000	Total RM'000
	Singapore RM'000	Malaysia RM'000	India RM'000	Greater China RM'000	Turkiye and Europe RM'000	Southeast Asia RM'000						
<i>Revenue and expenses</i>												
Revenue from external customers	1,317,337	874,968	815,404	298,633	1,500,368	-	53,899	241,328	39,038	1,431	-	5,142,406
Inter-segment revenue	2,356	1,980	-	-	-	-	635	167,978	61,934	253,225	(488,108)	-
Total segment revenue	1,319,693	876,948	815,404	298,633	1,500,368	-	54,534	409,306	100,972	254,656	(488,108)	5,142,406
EBITDA	390,872	248,274	123,372	9,057	302,821	(33)	13,029	89,079	78,584	183,983	(289,581)	1,149,457
Depreciation and impairment of property, plant and equipment	(41,733)	(53,597)	(32,245)	(26,755)	(94,676)	-	-	(9,861)	(6,578)	(576)	-	(266,021)
Depreciation of ROU assets	(77,956)	(6,036)	(6,044)	(16,468)	(32,815)	-	-	(7,266)	(3,276)	(1,632)	59,240	(92,253)
Amortisation of intangible assets	-	(293)	(2,030)	(495)	(3,228)	-	-	(5,881)	-	(2,389)	3,175	(11,141)
Foreign exchange differences	(68)	(571)	(7,844)	(334)	3,461	19	(1)	(55)	4,397	6,305	-	5,309
Finance income	837	3,131	3,715	295	22,803	36	1,014	2,862	3,810	4,792	(3,707)	39,588
Finance costs	(43,137)	(1)	(19,853)	(48,011)	(89,559)	-	(738)	(3,964)	(8,255)	(18,118)	46,415	(185,221)
Net monetary gain/(loss) arising from hyperinflationary economy	-	-	-	-	169,985	-	-	(5,227)	-	-	-	164,758
Share of profits of associates (net of tax)	-	-	906	-	-	5,207	-	-	-	-	-	6,113
Share of profits/(losses) of joint ventures (net of Others	418	-	112	-	-	-	-	(28)	-	-	-	502
	-	-	-	119,326	-	-	-	-	-	862,091	-	981,417
Profit before tax	229,233	190,907	60,089	36,615	278,792	5,229	13,304	59,659	68,682	1,034,456	(184,458)	1,792,508
Income tax expense	(42,897)	(46,069)	(16,937)	(3,003)	(102,437)	-	(2,500)	(14,509)	(4,943)	(7,249)	-	(240,544)
Profit for the period	186,336	144,838	43,152	33,612	176,355	5,229	10,804	45,150	63,739	1,027,207	(184,458)	1,551,964
<i>Assets and liabilities</i>												
Cash and cash equivalents	155,102	224,454	40,694	124,606	394,424	7,566	-	56,072	99,717	1,276,488	-	2,379,123
Other assets	20,613,107	6,606,460	8,457,026	3,091,715	9,557,633	55,023	-	2,270,944	5,579,722	5,355,550	(13,774,143)	47,813,037
Segment assets as at 31 December 2023	20,768,209	6,830,914	8,497,720	3,216,321	9,952,057	62,589	-	2,327,016	5,679,439	6,632,038	(13,774,143)	50,192,160
Loans and borrowings	-	-	551,012	3,682,839	755,088	-	-	7,941	2,891,484	423,023	-	8,311,387
Other liabilities	10,478,235	1,032,694	2,768,378	796,795	3,522,026	2,260	-	464,614	465,432	3,927,732	(13,936,043)	9,522,123
Segment liabilities as at 31 December 2023	10,478,235	1,032,694	3,319,390	4,479,634	4,277,114	2,260	-	472,555	3,356,916	4,350,755	(13,936,043)	17,833,510

*: Segment information on Assets and Liabilities is based on the last financial year-end.

**A NOTES TO THE INTERIM FINANCIAL REPORT
FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024**

A9 VALUATION OF PROPERTY, PLANT AND EQUIPMENT

The Group does not adopt a revaluation policy on its property, plant and equipment.

A10 SIGNIFICANT RELATED PARTY TRANSACTIONS

Related party transactions have been entered into in the normal course of business under negotiated terms. Other than the remuneration paid to the key management personnel, the significant related party transactions of the Group are as follows:

	Financial period ended	
	31 Mar 2024	31 Mar 2023
	RM'000	RM'000
Transactions with substantial shareholders*		
- Sales and provision of services	73	40
- Purchase and consumption of services	(5,849)	(3,769)
	<u> </u>	<u> </u>
Transactions with key management personnel*		
- Sales and provision of services	1,938	3,612
- Purchase and consumption of services	(30,626)	(31,644)
	<u> </u>	<u> </u>

*: Including parties directly/jointly-controlled by substantial shareholders or key management personnel.

**A NOTES TO THE INTERIM FINANCIAL REPORT
FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024**

A11 CHANGES IN THE COMPOSITION OF THE GROUP

- (a) On 29 February 2024, Pantai Holdings Sdn. Bhd., an indirect wholly-owned subsidiary of IHH, completed the acquisition of the entire equity interest in Bedrock Healthcare Sdn. Bhd. (“Bedrock”) for a total cash consideration of RM250.4 million on a cash free debt free basis, subject to closing adjustments (“Acquisition”). Upon completion of the Acquisition, Bedrock and its subsidiaries, namely Mestika Unik Sdn. Bhd. and Eminent Rock Sdn. Bhd. have been consolidated as subsidiaries of IHH.

The effects of the acquisition are as follows:

	Provisional RM'000
Identifiable assets acquired and liabilities assumed	
Property, plant and equipment	21,419
Right-of-use assets	49,997
Intangible assets	17,999
Interests in joint ventures	11,251
Inventories	4,518
Trade and other receivables	7,083
Cash and cash equivalents	41,429
Loans and borrowings	(15,092)
Lease liabilities	(1,403)
Trade and other payables	(18,315)
Deferred tax liabilities	(9,643)
Tax payable	(841)
Book value of net identifiable assets acquired	<u>108,402</u>
Net cash outflow arising from acquisition of subsidiary	
Purchase consideration in cash and cash equivalents	250,405
Less: cash and cash equivalents acquired	<u>(41,429)</u>
	<u>208,976</u>
Goodwill	
Total purchase consideration	250,405
Book value of net identifiable assets acquired	<u>(108,402)</u>
Goodwill	<u>142,003</u>

As at 31 March 2024, the Group is in the midst of performing a purchase price allocation (“PPA”) for the acquisition of Bedrock, and would adjust goodwill accordingly upon completion of the PPA.

- (b) On 6 and 28 March 2024, Gleneagles Development Pte. Ltd. (“GDPL”), an indirect wholly-owned subsidiary of IHH, completed the acquisition of a 0.88% shareholding in Gleneagles Healthcare India Private Limited (“GHIPL”) from the minority shareholders. Consequential thereto, the Group’s effective interest in GHIPL increased from 98.17% to 99.05%.

The above changes in the composition of the Group are not expected to have material effect on the earnings and net assets of the Group.

**A NOTES TO THE INTERIM FINANCIAL REPORT
FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024**

A12 SUBSEQUENT EVENTS

- (a) On 19 April 2024 and 21 May 2024, GDPL subscribed to 10,491,488 equity shares (First Tranche) and 91,479 equity shares (Second and Final Tranche) of GHIPL under the rights issue by GHIPL, for cash of approximately INR4,000 million (equivalent to RM227.1 million). Consequential thereto, the Group’s effective interest in GHIPL increased from 99.05% to 99.15%.
- (b) On 2 May 2024, Parkway Trust Management Limited (“PTM”), an indirect wholly-owned subsidiary of IHH, transferred 130,500 Parkway Life Real Estate Investment Trust (“PLife REIT”) units that it owned to its eligible employees in accordance to PTM’s long term incentive plan. Consequential thereto, the Group’s effective interest in PLife REIT was diluted from 35.56% to 35.54%.
- (c) On 21 May 2024, Chengdu Shenton Health Clinic Co., Ltd, an indirect 43.76% owned subsidiary of IHH, had been dissolved via voluntary liquidation.

A13 CONTINGENT LIABILITIES OR CONTINGENT ASSETS

There were no material contingent liabilities or contingent assets as at 29 May 2024.

A14 CAPITAL COMMITMENTS

	31 Mar 2024	31 Dec 2023
	RM'000	RM'000
a. Capital expenditure commitments		
<i>Property, plant and equipment and investment properties</i>		
- Contracted but not provided for	1,289,516	1,272,246
b. Other commitments		
Maximum amount committed for Fortis Open Offer ¹	1,901,699	1,884,497
Maximum amount committed for Malar Open Offer ¹	16,117	15,971
	<u>1,917,816</u>	<u>1,900,468</u>

¹ The actual number of Fortis Healthcare Limited (“Fortis”) shares and the actual number of Fortis Malar Hospitals Limited (“Malar”) shares that Northern TK Venture Pte. Ltd. (“NTK”) will be acquiring can only be determined at the end of the Fortis Open Offer and Malar Open Offer respectively.

On 13 November 2018, IHH acquired 31.17% equity interest in Fortis through a preferential allotment by Fortis to NTK, an indirect wholly-owned subsidiary of IHH. As a consequence of the preferential allotment by Fortis, NTK is required to carry out the following:

- (i) A mandatory open offer for acquisition of up to 197,025,660 equity shares of face value of INR10 each in Fortis, representing additional 26% of the Expanded Voting Share Capital of Fortis, at a price of not less than INR170 per share (“Fortis Open Offer”) or such higher price as required under the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
- (ii) In light of the acquisition of the controlling stake of Fortis, a mandatory open offer for acquisition of up to 4,894,308 fully paid up equity shares of face value of INR10 each in Malar, representing 26% of the paid-up equity shares of Malar at a price of INR58 per share (“Malar Open Offer”). The Malar Open Offer is subject to the completion of the Fortis Open Offer.

**A NOTES TO THE INTERIM FINANCIAL REPORT
FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024**

On 13 July 2018, NTK, together with IHH and PPL had made a public announcement to all the public shareholders who are eligible to tender their shares in the Fortis Open Offer and Malar Open Offer.

Subsequently on 14 December 2018, the Supreme Court of India passed an order in the matter of “Mr Vinay Prakash Singh v. Sameer Gehlaut & Ors.” [Contempt Petition (Civil) No. 2120 of 2018] (“Original Contempt Petition”), directing “status quo with regard to sale of the controlling stake in Fortis Healthcare to Malaysian IHH Healthcare Berhad be maintained” (“Interim Status Quo Order”). Pursuant thereto, decision was taken not to proceed with Fortis Open Offer and Malar Open Offer.

Vide its judgment dated 15 November 2019 (“Judgment”), the Supreme Court of India issued suo-moto contempt notice to, among others, Fortis, and its Registry to register a fresh contempt petition in regard to alleged violation of the Interim Status Quo Order (“Fortis Contempt Petition”).

On 22 September 2022, the Supreme Court pronounced the final order and on 23 September 2022, the written judgment was made available. The Supreme Court held, among others, that:

- (i) The Special Leave Petition (Civil) No. 20417 of 2017, the Original Contempt Petition (in which the Interim Status Quo Order was passed) and the Fortis Contempt Petition are disposed of.
- (ii) The Delhi High Court may consider issuing appropriate process and appointing forensic auditor(s) to analyse the transactions entered into between Fortis and RHT Health Trust and other related transactions.
- (iii) It will be open to the Delhi High Court to pass such directions as the facts and circumstances presented before it may justify.

Neither IHH, NTK or PPL are party to Daiichi Sankyo Co. Ltd’s (“Daiichi”) pending execution proceedings* before the Delhi High Court. Daiichi had moved Delhi High Court requesting the Delhi High Court to pass appropriate directions (in view of the Supreme Court Judgment) in connection with the forensic audit and the execution proceedings are ongoing.

Following the decision of the Supreme Court of India, on 16 November 2022, the Securities and Exchange Board of India (“SEBI”) had advised NTK to proceed with the Fortis Open Offer and the Malar Open Offer after obtaining an appropriate order from the Delhi High Court. Based on advice from legal counsel, NTK has made further representations to SEBI in relation to proceeding with the Fortis Open Offer and Malar Open Offer.

*: Daiichi filed execution proceedings before the Delhi High Court to enforce and execute an arbitral award issued in its favour (“Arbitral Award”). Pursuant to the Arbitral Award (which IHH Group is not a party to), Mr. Malvinder Mohan Singh and Mr. Shivinder Mohan Singh (“Singh Brothers”) and persons and entities related to them were directed to pay an amount of approximately INR 25.62 billion with interest to Daiichi in connection with a dispute relating to the sale of shares of Ranbaxy Laboratories Limited by the Singh Brothers to Daiichi.

**A NOTES TO THE INTERIM FINANCIAL REPORT
FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024**

A15 FAIR VALUE HIERARCHY

Fair value hierarchy

The table below analyses financial instruments carried at fair value. The different levels are defined as follows:

- Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Group can access at the measurement date.
- Level 2: Inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly.
- Level 3: Unobservable inputs for the asset or liability

	Level 1 RM'000	Fair value Level 2 RM'000	Level 3 RM'000	Total RM'000	Carrying amount RM'000
31 March 2024					
Financial assets					
Unquoted shares at FVOCI	-	-	207,115	207,115	207,115
Money market funds	-	174	-	174	174
Foreign exchange forward contracts	-	66,702	-	66,702	66,702
Cross currency swaps	-	128,757	-	128,757	128,757
Cross currency interest rate swaps	-	92,418	-	92,418	92,418
Interest rate swaps	-	246	-	246	246
Interest rate caps	-	3,430	-	3,430	3,430
Financial liabilities					
Foreign exchange forward contracts	-	(735)	-	(735)	(735)
Interest rate swaps	-	(6,039)	-	(6,039)	(6,039)
Cross currency swaps	-	(2,337)	-	(2,337)	(2,337)
Fixed rate medium term notes	-	(544,213)	-	(544,213)	(557,269)
31 December 2023					
Financial assets					
Unquoted shares at FVOCI	-	-	206,391	206,391	206,391
Money market funds	-	120,409	-	120,409	120,409
Foreign exchange forward contracts	-	70,184	-	70,184	70,184
Cross currency swaps	-	193,140	-	193,140	193,140
Cross currency interest rate swaps	-	83,227	-	83,227	83,227
Interest rate caps	-	4,365	-	4,365	4,365
Financial liabilities					
Foreign exchange forward contracts	-	(9,998)	-	(9,998)	(9,998)
Interest rate swaps	-	(9,120)	-	(9,120)	(9,120)
Cross currency swaps	-	(977)	-	(977)	(977)
Fixed rate medium term notes	-	(579,622)	-	(579,622)	(579,622)

Refer to Section B13 for fair value gain/(loss) recognised in the statement of profit or loss.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYIA'S LISTING REQUIREMENTS FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024

B1 REVIEW OF THE PERFORMANCE OF THE COMPANY AND ITS PRINCIPAL SUBSIDIARIES

	1st quarter ended		
	31 Mar 2024	31 Mar 2023	Variance
	RM'000	RM'000	%
<u>REVENUE</u>¹			
Singapore	1,550,991	1,317,337	18%
Malaysia	954,569	874,968	9%
India	981,452	815,404	20%
Greater China	368,889	298,633	24%
Turkiye and Europe	1,793,911	1,456,089	23%
Hospital and Healthcare	5,649,812	4,762,431	19%
IMU Health	-	53,899	-100%
Labs total revenue	446,426	407,271	10%
Less: Labs inter-segment revenue	(190,608)	(167,978)	-13%
Labs	255,818	239,293	7%
Others[^]	1,494	1,431	4%
Group (Excluding PLife REIT)	5,907,124	5,057,054	17%
PLife REIT total revenue	106,558	100,972	6%
Less: PLife REIT inter-segment revenue	(68,311)	(61,934)	-10%
PLife REIT	38,247	39,038	-2%
	5,945,371	5,096,092	17%
Adjustment for hyperinflationary economy ⁴	10,089	46,314	-78%
Group	5,955,460	5,142,406	16%
<u>EBITDA</u>²			
Singapore	468,616	390,872	20%
Malaysia	239,312	248,274	-4%
India	185,510	123,372	50%
Greater China	24,555	9,057	171%
Turkiye and Europe	376,225	296,832	27%
Southeast Asia	(8)	(33)	76%
Hospital and Healthcare	1,294,210	1,068,374	21%
IMU Health	-	13,029	-100%
Labs	96,614	93,173	4%
Others[^]	(25,597)	(41,410)	38%
Eliminations³	(101)	(61)	-66%
Group (Excluding PLife REIT)	1,365,126	1,133,105	20%
PLife REIT	83,401	78,584	6%
Eliminations³	(70,572)	(64,127)	-10%
	1,377,955	1,147,562	20%
Adjustment for hyperinflationary economy ⁴	(12,367)	1,895	NM
Group	1,365,588	1,149,457	19%

¹: Relates to external revenue only.

²: Relates to the EBITDA performance of each strategic business units, after elimination of dividend income from within the Group.

³: Relates to the elimination of inter-segment income and expenses.

⁴: Arises from the application of MFRS 129.

[^]: "Others" comprise mainly corporate office as well as other investment holding entities.

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYIA'S LISTING REQUIREMENTS
FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024**

Q1 2024 vs Q1 2023

The Group's Q1 2024 revenue and EBITDA increased 16% and 19% over Q1 2023. Excluding effects of MFRS 129, the Group's Q1 2024 revenue and EBITDA increased 17% and 20% respectively over Q1 2023.

The Group's Q1 2024 PATMI excluding exceptional items ("PATMI (Excl EI)") increased 22% to RM402.8 million. Excluding effects of MFRS 129, the Group's Q1 2024 PATMI (Excl EI) increased 30% over Q1 2023.

The divestment of IMU Health was completed on 31 March 2023, upon which, IMU Health ceased to contribute to the Group's results.

Hospital and Healthcare

Hospital and Healthcare's Q1 2024 revenue increased 19% to RM5,649.8 million while its Q1 2024 EBITDA increased 21% to RM1,294.2 million. The growth in revenue was driven by a sustained demand for quality healthcare services, a case-mix of more acute patients and price adjustments to counter inflation. The acquisitions of Kent on 14 February 2023 and Bedrock on 29 February 2024 also contributed to the increase.

Singapore hospital inpatient admissions decreased 1% to 15,427 in Q1 2024 while its revenue per inpatient admission increased 15% to RM64,716. Malaysia hospital inpatient admissions was flat at 58,714 in Q1 2024 while its revenue per inpatient admission increased 10% to RM10,699. India hospital inpatient admissions increased 1% to 73,151 in Q1 2024 while its revenue per inpatient admission increased 11% to RM11,698. Turkiye and Europe hospital inpatient admissions increased 2% to 66,925 in Q1 2024 while its revenue per inpatient admission increased 51% to RM13,838 with price adjustments, especially in Turkiye, to counter hyperinflation.

The increase in Hospital and Healthcare's Q1 2024 EBITDA was mainly driven by higher revenue, offset by higher staff cost and other operating expense such as utilities.

IMU Health

The divestment of IMU Health was completed on 31 March 2023, upon which, IMU Health ceased to contribute to the Group's results.

Labs

Labs' Q1 2024 total revenue increased 10% to RM446.4 million while its Q1 2024 EBITDA increased 4% to RM96.6 million. Labs' Q1 2024 total test volumes increased 5% to 24.2 million.

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYIA'S LISTING REQUIREMENTS
FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024**

PLife REIT

PLife REIT's Q1 2024 external revenue decreased 2% to RM38.2 million as a weakening Japanese Yen against RM eroded the revenue earned from the Japanese properties. PLife REIT's Q1 2024 EBITDA increased 6% to RM83.4 million. EBITDA increased mainly due to contribution from two nursing homes acquired in October 2023, and higher inter-segment rental income from the hospitals in Singapore.

Others

Q1 2024 revenue increased 4% to RM1.5 million while EBITDA losses decreased 38% to RM25.6 million. EBITDA losses decreased mainly due to higher inter-segment management fee income from the other business units and lower staff costs.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYIA'S LISTING REQUIREMENTS FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024

B2 MATERIAL CHANGE IN QUARTERLY RESULTS

	1st quarter ended 31 Mar 2024 RM'000	4th quarter ended 31 Dec 2023 RM'000	Variance %
<u>REVENUE</u>¹			
Singapore	1,550,991	1,441,941	8%
Malaysia	954,569	964,092	-1%
India	981,452	911,934	8%
Greater China	368,889	352,214	5%
Turkiye and Europe	1,793,911	1,564,495	15%
Hospital and Healthcare	5,649,812	5,234,676	8%
Labs total revenue	446,426	420,203	6%
Less: Labs inter-segment revenue	(190,608)	(176,594)	-8%
Labs	255,818	243,609	5%
Others [^]	1,494	1,394	7%
Group (Excluding PLife REIT)	5,907,124	5,479,679	8%
PLife REIT total revenue	106,558	102,147	4%
Less: PLife REIT inter-segment revenue	(68,311)	(64,756)	-5%
PLife REIT	38,247	37,391	2%
	5,945,371	5,517,070	8%
Adjustment for hyperinflationary economy ⁴	10,089	(224,427)	104%
Group	5,955,460	5,292,643	13%
<u>EBITDA</u>²			
Singapore	468,616	412,437	14%
Malaysia	239,312	211,257	13%
India	185,510	144,307	29%
Greater China	24,555	24,236	1%
Turkiye and Europe	376,225	384,019	-2%
Southeast Asia	(8)	(77)	90%
Hospital and Healthcare	1,294,210	1,176,179	10%
Labs	96,614	73,925	31%
Others [^]	(25,597)	(38,911)	34%
Eliminations ³	(101)	22	NM
Group (Excluding PLife REIT)	1,365,126	1,211,215	13%
PLife REIT	83,401	87,720	-5%
Eliminations ³	(70,572)	(66,977)	-5%
	1,377,955	1,231,958	12%
Adjustment for hyperinflationary economy ⁴	(12,367)	(162,313)	92%
Group	1,365,588	1,069,645	28%

¹: Relates to external revenue only.

²: Relates to the EBITDA performance of each strategic business units, after elimination of dividend income from within the Group.

³: Relates to the elimination of inter-segment income and expenses.

⁴: Arises from the application of MFRS 129.

[^]: "Others" comprise mainly corporate office as well as other investment holding entities.

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYIA'S LISTING REQUIREMENTS
FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024**

Q1 2024 vs Q4 2023

The Group's quarter-on-quarter revenue and EBITDA increased 13% and 28% respectively. Excluding effects of MFRS 129, the Group's quarter-on-quarter revenue and EBITDA increased 8% and 12% respectively.

The Group's PATMI (Excl EI) increased 52% quarter-on-quarter. Excluding effects of MFRS 129, the Group's quarter-on-quarter PATMI (Excl EI) increased 15%.

Hospital and Healthcare

Hospital and Healthcare quarter-on-quarter revenue and EBITDA increased 8% and 10% respectively.

Singapore hospital inpatient admissions increased 3% quarter-on-quarter, while its revenue per inpatient admission increased 1%. Malaysia hospital inpatient admissions decreased 5% quarter-on-quarter, while its revenue per inpatient admission increased 5%. India hospital inpatient admissions was flat quarter-on-quarter, while its revenue per inpatient admission increased 6%. Turkiye and Europe hospital inpatient admissions increased 2% quarter-on-quarter, while its revenue per inpatient admission increased 24%.

Labs

Labs total revenue increased 6% quarter-on-quarter and EBITDA increased 31%. EBITDA increased from a low base in Q4 2023 where higher provision for doubtful debts was recognised.

PLife REIT

Plife REIT's external revenue increased 2% quarter-on-quarter due to contribution from two nursing homes acquired in October 2023. Plife REIT's EBITDA decreased 5% quarter-on-quarter mainly from a high base whereby valuation gains on investment properties of RM5.8 million was recognised.

Others

Revenue increased 7% quarter-on-quarter while EBITDA losses decreased. EBITDA losses decreased 34% quarter-on-quarter mainly due to lower inter-segment service contract fee expense in Q1 2024.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYIA'S LISTING REQUIREMENTS FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024

B3 CURRENT YEAR FINANCIAL PROSPECTS

With growing healthcare needs and demand both locally and from the region, the Group is strategically poised to meet the increasing demand for quality healthcare services and will broaden its reach and enhance its offerings across key markets it operates.

The Group's strategic priorities encompasses both organic and inorganic growth drivers, expansion of IHH's services in the healthcare continuum, developing new engines of growth as well as turning around underperforming assets. On 29 February 2024, the Group completed its acquisition of Timberland Medical Centre in Kuching, Sarawak, strengthening its position as a leading healthcare provider across Malaysia. Furthermore, as part of the Group's ongoing strategic initiatives, Gleneagles Global Hospitals in India underwent a rebranding in March 2024 to become "Gleneagles Hospitals". The six hospitals under Gleneagles Hospitals are implementing infrastructure upgrades to improve the overall patient experience, aligned with its commitment to deliver quality care and excellence in healthcare service. As part of the Group's efforts at deploying AI and other innovative technologies to elevate patient care and to provide more holistic healthcare solutions, the Group recently invested in an AI start-up for diagnosing sleep apnea and other sleep issues. On 10 May 2024, the Group officially opened its Mount Elizabeth Proton Therapy Centre in Singapore, reinforcing its position as Asia's leading Centre of Excellence in comprehensive cancer care.

Despite the strong underlying demand for quality healthcare services, the Group is cognisant of the cost pressures arising from sustained inflation, rising energy prices and higher staff costs. These challenges are not unique to the healthcare industry. The Group is confident that it would be able to maintain a tight rein on costs and leverage operational synergies from its international network to achieve cost savings, while at the same time, ensuring the delivery of high-quality care and value to its patients. The Group is also in the midst of transforming some of its workflows and processes through greater digitisation and optimisation for greater efficiency.

Looking forward, the Group anticipates navigating a landscape that continues to be marked by global economic and geo-political headwinds. However, the Group is confident that it would be able to manage these macroeconomic uncertainties and keep to its long-term growth trajectory that is underpinned by its strong fundamentals, driven by its robust expansion initiatives and fueled by healthcare megatrends.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYIA’S LISTING REQUIREMENTS FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024

B4 PROFIT FORECAST/GUARANTEE

Not applicable as no profit forecast/guarantee was issued.

B5 TAXATION

	1st quarter ended	
	31 Mar 2024	31 Mar 2023
	RM'000	RM'000
Current tax expense	137,013	118,101
Deferred tax (credit)/expense	(131,802)	122,443
	<u>5,211</u>	<u>240,544</u>

Q1 2024 and Q1 2023 effective tax rates* were 0.6% and 13.5% respectively.

In Q1 2024, Acibadem Holdings recognised RM293.4 million deferred tax credit relating to an exemption allowed by the Turkiye government to increase the tax base of the assets in the local tax books. Excluding these deferred tax credit recognised, Q1 2024 effective tax rates* would be 32.3%.

The Group’s effective tax rates differ from the Malaysia statutory tax rate mainly due to certain non-taxable income and non-tax deductible expenses (refer to page 2 for list of exceptional items). In addition, the re-indexation of non-monetary assets upon the application of MFRS 129 to the Group’s entities in Turkiye results in the recognition of deferred tax liabilities, which leads to a higher effective tax rate.

* Effective tax rate, after adjusting for the Group’s share of profits of associates and joint ventures

B6 STATUS OF CORPORATE PROPOSALS

Save as disclosed below, there were no other corporate proposals announced but not completed as at 29 May 2024:

1. Following the subscription of 235,294,117 new equity shares of face value of Indian Rupee (“INR”) 10 each (“Fortis Shares”) in Fortis Healthcare Limited (“Fortis”) through preferential allotment by Fortis to an indirect wholly-owned subsidiary of IHH, Northern TK Venture Pte Ltd (“NTK” or the “Acquirer”);
 - (i) Mandatory Open Offer for acquisition of up to 197,025,660 Fortis Shares representing additional 26.10% of the Expanded Voting Share Capital (as defined herein) of Fortis by the Acquirer (“Fortis Open Offer”); and
 - (ii) Mandatory Open Offer for acquisition of up to 4,894,308 fully paid up equity shares of face value of INR10 each, representing 26.11% of the fully diluted voting equity share capital of Fortis Malar Hospitals Limited (“Malar”) by the Acquirer (“Malar Open Offer”).

Refer to Section A14 for details and status of the Fortis Open Offer and Malar Open Offer.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYIA'S LISTING REQUIREMENTS FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024

B7 LOANS, BORROWINGS AND OVERDRAFTS

(a) Breakdown of the Group's loans, borrowings and overdrafts:

	31 Mar 2024	31 Dec 2023
	RM'000	RM'000
Non-current		
Secured		
Bank loans	1,179,682	1,086,112
Loans from corporates	4,040	4,240
Unsecured		
Bank loans	4,024,138	4,003,420
Fixed rate medium term notes	557,269	579,622
Loans from corporates*	984,021	977,173
	<u>6,749,150</u>	<u>6,650,567</u>
Current		
Secured		
Bank overdrafts	37,171	77,885
Bank loans	171,861	135,096
Loans from corporates	2,286	2,328
Unsecured		
Bank loans	1,456,302	1,522,316
Loans from corporates	1,088	1,080
	<u>1,668,708</u>	<u>1,738,705</u>
Total	<u><u>8,417,858</u></u>	<u><u>8,389,272</u></u>

* Includes loans from non-controlling interests of RM983,536,000 (2023: RM976,695,000)

Breakdown of the Group's loans, borrowings and overdrafts by source currency, in RM equivalent:

	31 Mar 2024	31 Dec 2023
	RM'000	RM'000
Hong Kong Dollar	3,100,640	3,093,530
Japanese Yen	1,927,819	2,102,206
Singapore Dollar	1,022,819	789,278
Indian Rupees	662,917	629,508
Renminbi	645,011	602,393
Euro	522,815	832,371
Turkish Lira	360,982	321,154
Ringgit Malaysia	144,864	-
Macedonian Denar	28,413	17,275
Others	1,578	1,557
	<u>8,417,858</u>	<u>8,389,272</u>

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYIA'S LISTING REQUIREMENTS FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024

B8 FINANCIAL DERIVATIVE INSTRUMENTS

The Group's outstanding net derivative financial instruments as at 31 March 2024:

	Notional amount as at 31 Mar 2024 RM'000	Fair value amount as at 31 Mar 2024 RM'000
Derivative assets		
Foreign exchange forward contracts		
- Within 1 year	457,917	5,857
- Between 1 - 3 years	181,064	51,986
- More than 3 years	170,566	8,859
	<u>809,547</u>	<u>66,702</u>
Interest rate swaps		
- More than 3 years	2,189,958	246
Interest rate caps		
- Within 1 year	366,974	194
- Between 1 - 3 years	638,722	2,038
- More than 3 years	106,254	1,198
	<u>1,111,950</u>	<u>3,430</u>
Cross currency interest rate swaps		
- Between 1 - 3 years	287,482	92,418
Cross currency swaps		
- Within 1 year	188,151	128,757
	<u>4,587,088</u>	<u>291,553</u>
Derivative liabilities		
Interest rate swaps		
- More than 3 years	513,949	(6,039)
Foreign exchange forward contracts		
- Within 1 year	37,012	(735)
Cross currency swaps		
- Within 1 year	438,869	(1,888)
- Between 1 - 3 years	30,853	(449)
	<u>469,722</u>	<u>(2,337)</u>
	<u>1,020,683</u>	<u>(9,111)</u>

Foreign exchange forward contracts

Foreign exchange forward contracts are entered by the Group to hedge against exchange rate exposures on some balances denominated in currencies other than the functional currency of the entity that recognised the foreign currency balances. The fair value of foreign exchange forward contract is determined based on prevailing market rate.

Interest rate caps

Interest rate caps are entered by the Group to protect against an increase in interest rates beyond the pre-determined cap rate.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYIA'S LISTING REQUIREMENTS FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024

Cross currency interest rate swaps and cross currency swaps

Cross currency interest rate swaps and cross currency swaps are entered by the Group to hedge the interest rate fluctuations on the floating rate borrowings, and to realign certain borrowings to the same currency of the Group's foreign investments to achieve a natural hedge. The fair values of cross currency interest rate swaps and cross currency swaps are determined based on bank quotes.

Interest rate swaps

Interest rate swaps are entered by the Group to hedge against interest rate fluctuations on some floating rate borrowings. The fair value of interest rate swaps is determined based on bank quotes.

There are no changes to the Group's financial risk management policies and objectives in managing these derivative financial instruments and its related accounting policies. Refer to Section B13 for the fair value gain/loss recognised in the statement of profit or loss.

B9 FAIR VALUE CHANGES OF FINANCIAL LIABILITIES

Other than as disclosed in Section A15 the Group does not remeasure its financial liabilities and derivatives at reporting date. The changes in fair value recognised through profit or loss are disclosed in Section B13.

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYIA'S LISTING REQUIREMENTS
FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024**

B10 MATERIAL LITIGATIONS

The following are the material litigations of the Group:

1) In respect of Escorts Heart Institute and Research Centre Limited (“EHIRCL”), an indirect subsidiary of IHH:

- (a) The Delhi Development Authority (“DDA”) had terminated the lease deeds and allotment letters relating to land parcels on which a hospital of EHIRCL exists. The matter is currently pending before the High Court of Delhi. Consequent to the termination, DDA issued show cause notice and initiated eviction proceedings against EHIRCL. The eviction proceedings initiated before the Estate Officer were challenged before the Supreme Court of India. The Supreme Court of India, vide its order dated 14 November 2019, has quashed the show cause notice for eviction proceedings. Based on external legal counsel advice, EHIRCL will be able to suitably defend the termination of lease deeds and allotment letters and accordingly considers that no adjustments are required to the financial statements.
- (b) In relation to the judgement of the High Court of Delhi relating to provision of free treatment/beds to patients of the economically weaker sections of society, the Directorate of Health Services (“DoHS”), Government of NCT of Delhi, appointed a firm to calculate “unwarranted profits” arising to EHIRCL due to alleged non-compliance. Following various hearings and appeals between 2014 and 2018, DoHS in May 2018, passed an order imposing a demand of INR5.0 billion (equivalent to RM286.0 million) which was challenged by EHIRCL before the High Court of Delhi. Through an order dated 1 June 2018, the High Court of Delhi has issued notice and directed that no coercive steps may be taken subject to EHIRCL depositing a sum of INR50.0 million (equivalent to RM2.9 million) before the DoHS. EHIRCL deposited INR50.0 million (equivalent to RM2.9 million) on 20 June 2018. Matter is sub judice before the High Court of Delhi. Based on its internal assessment and advice from its counsel, on the basis of the documents available, EHIRCL believes that it is in compliance of the conditions of free treatment and free beds to patients of economic weaker sections, has a good case of success. and expects the demand to be set aside.

2) In respect of Northern TK Venture Pte Ltd (“NTK”), an indirect wholly-owned subsidiary of IHH:

- (a) On 16 October 2023, NTK had filed a claim against Daiichi in the Tokyo District Court (“Court”) in Japan (“Claim”). NTK’s position is that Daiichi has caused losses to NTK by preventing NTK from proceeding with the Fortis Open Offer and the Malar Open Offer. The Claims filed by NTK against Daiichi are tort claims premised on Daiichi’s unlawful interference with NTK’s trade or business, conspiracy of Daiichi and other persons, malicious falsehood and defamation under the applicable substantive laws. NTK is seeking inter alia the following reliefs from Daiichi in accordance with the applicable substantive laws: (i) JPY 20 billion as damages to NTK, plus interest at 3% per annum; (ii) an injunction to restrain Daiichi from defaming NTK in the future; and (iii) Daiichi to publish a statement on its website, and to deliver a statement to SEBI, to vindicate NTK’s reputation. NTK has expressly reserved its rights to amend and/or supplement the reliefs it is seeking from Daiichi. Hearings before the Court took place on 26 December 2023, 22 February 2024 and 14 May 2024. The next hearing is scheduled for 20 August 2024.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYIA'S LISTING REQUIREMENTS FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024

B11 DIVIDENDS

No dividends were declared or paid by the Company during the financial period ended 31 March 2024.

B12 EARNINGS PER SHARE ("EPS")

Basic earnings per share were calculated by dividing the Group's net profit attributable to shareholders less distribution to holders of the perpetual securities, by the weighted average number of ordinary shares in issue during the financial period.

	1st quarter ended	
	31 Mar 2024	31 Mar 2023
	RM'000	RM'000
Basic and diluted earnings per share is based on:		
Net profit attributable to ordinary shareholders	767,972	1,390,519
Net profit attributable to ordinary shareholders (excluding EI)	402,846	329,866
	<u>8,806,992</u>	<u>8,806,212</u>
Basic EPS		
	'000	'000
Weighted average number of shares	8,806,992	8,806,212
	sen	sen
Basic EPS	8.72	15.79
Basic EPS (excluding EI)	4.57	3.75
	<u>8.72</u>	<u>15.79</u>
	<u>4.57</u>	<u>3.75</u>

Diluted earnings per share

For diluted EPS, the weighted average number of ordinary shares in issue is adjusted to assume conversion of all potentially dilutive ordinary shares.

	1st quarter ended	
	31 Mar 2024	31 Mar 2023
	'000	'000
Weighted average number of ordinary shares used in calculation of basic earnings per share	8,806,992	8,806,212
Weighted number of unissued ordinary shares from share options under EOS	178	71
Weighted average number of dilutive ordinary shares for computation of diluted EPS	<u>8,807,170</u>	<u>8,806,283</u>
	sen	sen
Diluted EPS	8.72	15.79
Diluted EPS (excluding EI)	4.57	3.75
	<u>8.72</u>	<u>15.79</u>
	<u>4.57</u>	<u>3.75</u>

At 31 March 2024, 316,000 (31 March 2023: 1,676,000) outstanding EOS options were excluded from the diluted weighted average number of ordinary shares calculation as their effect would have been anti-dilutive.

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYIA'S LISTING REQUIREMENTS FOR THE FIRST QUARTER AND FINANCIAL PERIOD ENDED 31 MARCH 2024

B13 NOTES TO THE STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	1st quarter ended	
	31 Mar 2024	31 Mar 2023
	RM'000	RM'000
Dividend income	112	-
Other operating income	83,928	104,408
Foreign exchange differences	1,542	5,309
Impairment loss made		
- Property, plant and equipment	(1,899)	(112)
- Trade and other receivables	(15,249)	(34,070)
Write off:		
- Property, plant and equipment	(230)	(95)
- Trade and other receivables	(10,922)	(1,125)
- Inventories	(846)	(1,459)
Change in fair value of investment properties	144	(792)
Gain on disposal of property, plant and equipment	968	3,486
Gain on disposal of subsidiaries	-	981,417
Finance income		
Interest income	40,427	18,529
Exchange gain on net borrowings	21,995	16,225
Fair value gain on financial instruments	16,309	4,834
	78,731	39,588
Finance costs		
Interest on loans and borrowings	(129,181)	(112,978)
Interest on lease liabilities	(43,405)	(43,410)
Fair value loss on financial instruments	(69,382)	(14,753)
Other finance costs	(15,470)	(14,080)
	(257,438)	(185,221)